All In Biotech

Drug Trial Radar · NCT00602472

BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes

A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg) Administered Orally Once Daily Over 24 Weeks, With an Open-label Extension to One Year (Placebo Patients Switched to BI 1356), in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With a Sulphonylurea

Last checked: Nov 19, 2026Latest source record: Mar 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,058 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,058

Actual

Start

Feb 2008

Primary completion

May 2009

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jan 28, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in combination with a sulphonylurea in patients with type 2 diabetes mellitus with insufficient glycaemic control.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • linagliptinDrug

    active

  • placeboDrug

    placebo to linagliptin 5 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1c Change From Baseline to Week 24Time frame: Baseline and week 24

Locations

100 sites in 11 countries. Site status is shown where the registry gives one.

  • 1218.18.54001 Boehringer Ingelheim Investigational Site

    Capital Federal, Argentina

  • 1218.18.54002 Boehringer Ingelheim Investigational Site

    Capital Federal, Argentina

  • 1218.18.54004 Boehringer Ingelheim Investigational Site

    Capital Federal, Argentina

  • 1218.18.54005 Boehringer Ingelheim Investigational Site

    Capital Federal, Argentina

  • 1218.18.54010 Boehringer Ingelheim Investigational Site

    Capital Federal, Argentina

  • 1218.18.54009 Boehringer Ingelheim Investigational Site

    Córdoba, Argentina

  • 1218.18.54013 Boehringer Ingelheim Investigational Site

    Córdoba, Argentina

  • 1218.18.54014 Boehringer Ingelheim Investigational Site

    Corrientes, Argentina

  • 1218.18.54003 Boehringer Ingelheim Investigational Site

    Mar del Plata, Argentina

  • 1218.18.54012 Boehringer Ingelheim Investigational Site

    Mar del Plata, Argentina

  • 1218.18.54011 Boehringer Ingelheim Investigational Site

    Mendoza, Argentina

  • 1218.18.54015 Boehringer Ingelheim Investigational Site

    Parque Velez Sarfield, Argentina

  • 1218.18.54006 Boehringer Ingelheim Investigational Site

    Rosario, Argentina

  • 1218.18.54007 Boehringer Ingelheim Investigational Site

    Salta, Argentina

  • 1218.18.32005 Boehringer Ingelheim Investigational Site

    Bruges, Belgium

  • 1218.18.32007 Boehringer Ingelheim Investigational Site

    Brussels, Belgium

  • 1218.18.32006 Boehringer Ingelheim Investigational Site

    Edegem, Belgium

  • 1218.18.32004 Boehringer Ingelheim Investigational Site

    Genk, Belgium

  • 1218.18.32003 Boehringer Ingelheim Investigational Site

    Ghent, Belgium

  • 1218.18.32002 Boehringer Ingelheim Investigational Site

    Huy, Belgium

  • 1218.18.32001 Boehringer Ingelheim Investigational Site

    Liège, Belgium

  • 1218.18.01005 Boehringer Ingelheim Investigational Site

    Calgary, Alberta, Canada

  • 1218.18.01010 Boehringer Ingelheim Investigational Site

    Calgary, Alberta, Canada

  • 1218.18.01003 Boehringer Ingelheim Investigational Site

    Vancouver, British Columbia, Canada

  • 1218.18.01011 Boehringer Ingelheim Investigational Site

    Vancouver, British Columbia, Canada

  • 1218.18.01006 Boehringer Ingelheim Investigational Site

    Etobicoke, Ontario, Canada

  • 1218.18.01009 Boehringer Ingelheim Investigational Site

    Hamilton, Ontario, Canada

  • 1218.18.01002 Boehringer Ingelheim Investigational Site

    London, Ontario, Canada

  • 1218.18.01012 Boehringer Ingelheim Investigational Site

    Oakville, Ontario, Canada

  • 1218.18.01008 Boehringer Ingelheim Investigational Site

    Sarnia, Ontario, Canada

  • 1218.18.01001 Boehringer Ingelheim Investigational Site

    Toronto, Ontario, Canada

  • 1218.18.01004 Boehringer Ingelheim Investigational Site

    Montague, Prince Edward Island, Canada

  • 1218.18.01007 Boehringer Ingelheim Investigational Site

    Saskatoon, Saskatchewan, Canada

  • 1218.18.86001 Boehringer Ingelheim Investigational Site

    Beijing, China

  • 1218.18.86002 Boehringer Ingelheim Investigational Site

    Beijing, China

  • 1218.18.86004 Boehringer Ingelheim Investigational Site

    Beijing, China

  • 1218.18.86013 Boehringer Ingelheim Investigational Site

    Chengdu, Sichuan Province, China

  • 1218.18.86009 Boehringer Ingelheim Investigational Site

    Dalian, China

  • 1218.18.86011 Boehringer Ingelheim Investigational Site

    Guangzhou, China

  • 1218.18.86014 Boehringer Ingelheim Investigational Site

    Haerbin, China

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.